SciBase Reschedules Trading Date for Rights Issue
News related to:SciBase Holding AB · 2 min read
STOCKHOLM, Sept. 15, 2026 /CourierPR/ -- SciBase Holding AB, a global medical technology company specializing in early detection and prevention in dermatology, has announced an update to its ongoing rights issue. The company has revised the first day of trading in subscription rights and paid-up subscribed shares (BTA) on the Nasdaq First North Growth Market from September 15, 2026, to September 16, 2026.
The subscription period for the rights issue remains unchanged and will run from September 15, 2026, to September 29, 2026. SciBase, which develops and commercializes Nevisense, a point-of-care platform combining AI and advanced EIS technology, has been listed on the Nasdaq First North Growth Market since June 2, 2015.
The company's Chief Financial Officer, Michael Colérus, stated, "We are committed to ensuring a smooth and transparent process for our shareholders and stakeholders. The update to the trading date reflects our ongoing efforts to provide clarity and support for our investors."
The rights issue is part of SciBase's strategy to raise capital and further its research and development efforts. The company's commitment to proactive skin health management and early detection is aimed at minimizing patient suffering and improving clinical outcomes.
SciBase's leadership emphasized the importance of maintaining a clear and consistent communication channel with its shareholders.
The company's rights issue is subject to certain legal and regulatory requirements, and the availability of the rights to non-Swedish residents may be restricted by the laws of their respective jurisdictions. SciBase has prepared an information document for the rights issue, which is available on its website.
The rights issue is not an offer to acquire or subscribe for securities in the United States, and the securities involved have not been registered under the U.S. Securities Act of 1933. SciBase advises potential investors to familiarize themselves with the relevant laws and regulations in their jurisdictions.
The update to the trading date is part of SciBase's ongoing efforts to ensure a smooth and efficient rights issue process. The company remains focused on its mission to enhance diagnostic accuracy and improve patient outcomes in the field of dermatology.